Söndag 24 November | 14:03:32 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-19 08:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-20 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-06-09 - Årsstämma
2023-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-10 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2022-06-09 - Årsstämma
2022-04-20 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-03 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2020-06-02 - Årsstämma
2020-05-15 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-06-12 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2019-06-11 - Årsstämma
2019-05-15 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-12 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2018-05-29 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-10-23 - Extra Bolagsstämma 2017
2017-08-24 - Kvartalsrapport 2017-Q2
2017-06-13 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2017-06-12 - Årsstämma
2017-05-17 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-27 - X-dag ordinarie utdelning NANEXA 0.00 SEK
2016-05-26 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-06 - Extra Bolagsstämma 2016
2016-02-25 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Nanexa är ett drug delivery-bolag med en egenutvecklad plattform som används för formulering av injicerbara depåläkemedel som skapar en tillförsel av läkemedel till blodet. PharmaShell processen baseras på ALD (Atomic Layer Deposition) teknologin som innesluter läkemedelspartiklar med ett tunt skal och skapar möjlighet för läkemedelsbolag att utveckla nya produkter. Nanexa har samarbete med flertalet läkemedelsbolag, huvudsakligen runtom den nordiska marknaden.
2024-05-15 15:45:00

The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2024, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.

The income statement and balance sheet were adopted, together with the board of directors’ proposal for allocation of the company’s result. The board of directors and CEO were discharged from liability for the financial year 2023.

Göran Ando, Richard Davis, Jakob Dynnes Hansen, Eva Nilsagård and Birgit Stattin Norinder were re-elected, and Hanna Tilus was elected, as members of the board. Göran Ando was re-elected as chairman of the board.

The AGM voted on directors’ fees in accordance with the nomination committee’s proposal as follows:

Remuneration shall be paid with SEK 260,000 for the chairman and with SEK 130,000 to other board members not employed by the company. Furthermore, SEK 100,000 shall be paid to the chairman of the audit committee and SEK 50,000 to each other member of the audit committee.

The registered accounting firm Öhrlings PricewaterhouseCoopers AB was appointed auditor. Niclas Bergenmo will continue as auditor in charge.

The proposal from the nomination committee regarding the establishment of a nomination committee and instructions to the nomination committee were approved.

In accordance with the board of directors’ proposal, the AGM resolved on changes to the provisions of the articles of association concerning the limits for the company’s share capital and number of shares.

The AGM further resolved to adopt the board of directors’ proposals regarding authorizations for the board to decide on rights issues and directed issues.